Summary
March 2007, Vol. 6, No. 2, Pages 207-215 , DOI 10.1517/14740338.6.2.207

Histologically defined biomarkers in toxicology

Cormac G Kilty1, Joe Keenan2 & Martin Shaw3
1Chief Scientific Officer, Biotrin International, 93 The Rise, Mount Merrion, Dublin, Ireland
2Principal Scientific Officer, Biotrin International, 93 The Rise, Mount Merrion, Dublin, Ireland
3Senior Scientific Officer, Biotrin International, 93 The Rise, Mount Merrion, Dublin, Ireland.
Author for correspondence



Histopathology is the gold standard when defining toxicological effects, but it is invasive, time consuming and expensive. Using biomarkers linked to distinct, defined cell types and tissues may provide a direct link to histopathology without its drawbacks and it also provides increased sensitivity and specificity. Furthermore, as histological testing is often impractical in human subjects, using biomarkers with a known histological distribution may fill the need of localising toxic injury to distinct organs or tissues. This paper discusses how, by using biomarkers with a known cellular origin (histologically defined biomarkers), toxic effects may be found earlier and at lower doses of compound, leading to potential savings in drug development.

Full Text | PDF (285 KB) | PDF Plus (317 KB)

Forward Links to Citing Articles

Hisaharu Yamada. (2009) Evaluation methods for nephrotoxicity. Folia Pharmacologica Japonica 133:3, 154-157
Online publication date: 1-Feb-2009.
CrossRef
 

Prev. Article | Next Article
View/Print PDF (285 KB)
View PDF Plus (317 KB)
Add to favourite
Email to a friend
TOC Alert | Citation Alert What is RSS?

 
 
Quick Search
for 
Authors:
Cormac G Kilty
Joe Keenan
Martin Shaw
Keywords:
ALT
AST
cardiotoxicity
clara cell protein
diabetes
GLDH
glutathione S-transferase
hepatotoxicity
Histomics
NAG
nephrotoxicity
proteomics
pulmonary toxicity
RPA-1
sorbitol dehydrogenase
troponin